Trial Profile
Combination Immunotherapy With Interferon-gamma and Nivolumab for Patients With Advanced Solid Tumors: A Phase 1 Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Interferon gamma-1b (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions
- 26 Nov 2019 Status changed from recruiting to completed.
- 16 Mar 2019 Outcomes of population pharmacokinetics of subcutaneous IFN-gamma 1b in patients with solid tumors using data (n=18) from this study, were presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 06 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2021.